Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
TRAF6-BECN1 signaling axis is critical for autophagy induction and functionally implicated in cancer progression. Here, we report that AMP-activated protein kinase alpha 1 (, ) is positively involved in autophagy induction and cancer progression by regulating TRAF6-BECN1 signaling axis. Mechanistically, AMPKα1 interacted with TRAF6 and BECN1. It also enhanced ubiquitination of BECN1 and autophagy induction. -knockout (KO) HEK293T or -knockdown (KD) THP-1 cells showed impaired autophagy induced by serum starvation or TLR4 (Toll-like receptor 4) stimulation. Additionally, KD THP-1 cells showed decreases of autophagy-related and autophagosome-related genes induced by TLR4. KO A549 cells exhibited attenuation of cancer migration and invasion induced by TLR4. Moreover, primary non-small cell lung cancers (NSCLCs, = 6) with low AMPKαl levels showed markedly decreased expression of genes related to autophagy, cell migration and adhesion/metastasis, inflammation, and TLRs whereas these genes were significantly upregulated in NSCLCs ( = 5) with high AMPKαl levels. Consistently, attenuation of cancer migration and invasion could be observed in KO MDA-MB-231 and KO MCF-7 human breast cancer cells. These results suggest that AMPKα1 plays a pivotal role in cancer progression by regulating the TRAF6-BECN1 signaling axis for autophagy induction.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694660 | PMC |
| http://dx.doi.org/10.3390/cancers12113289 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Moyamoya Syndrome in Patients With Down Syndrome and Acute Lymphoblastic Leukemia.
Pediatr Blood Cancer
September 2025
Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia, USA.
Moyamoya syndrome (MMS) is a chronic vasculopathy characterized by progressive stenosis of intracerebral arteries, leading to an increased risk of stroke. Children with Down syndrome (DS) are at an increased risk of co-occurring medical conditions, including MMS and leukemia. We report four patients with the triad of DS, MMS, and acute lymphoblastic leukemia (ALL).
View Article and Find Full Text PDFBio-ethical issues of research in Sub-Saharan Africa.
Monash Bioeth Rev
September 2025
Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Legon, Accra, Ghana.
This paper examines bioethical considerations of research conducted in Sub-Saharan Africa (SSA), where a notable scarcity persists in literature addressing region-specific bioethical issues. Although bioethics-related activities have encountered challenges surpassing existing protocol safeguards, emerging evidence demonstrates growing recognition of integrated scientific and ethical principles within African medical research. Maintaining research continuity in resource-limited settings necessitates bridging critical gaps between informed consent procedures and participants' actual understanding.
View Article and Find Full Text PDFBRAF positive Langerhans cell sarcoma arising from CALR positive myeloproliferative neoplasm: evidence of a clonal progenitor.
Virchows Arch
September 2025
Department of Pathology & Laboratory Medicine, Cleveland Clinic Florida, Weston, FL, USA.
Langerhans cell sarcoma (LCS) is an aggressive malignant neoplasm with a Langerhans cell immunophenotype and high-grade cytological features. Occasionally, it can coexist with other hematopoietic neoplasms with proven clonal relationship. Most of these neoplasms were found to be of lymphoid origin.
View Article and Find Full Text PDFAssociation Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial Carcinoma.
Clin Genitourin Cancer
August 2025
Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA.
Background: Combination therapy with enfortumab vedotin plus pembrolizumab (EV+P) is now the preferred first-line (1L) therapy for advanced urothelial carcinoma (aUC), but prognostic indicators for patients on 1L EV+P have not yet been described.
Patients And Methods: We conducted a retrospective cohort study of patients receiving 1L EV+P for aUC. We analyzed deidentified electronic health record data from the Flatiron Health database to identify adults with aUC who initiated EV+P between April 3, 2023 and December 31, 2024.
Mendelian Randomization Study: The Impact of Gut Microbiota on Survival in HR+ Breast Cancer Patients Under Different Treatment Regimens Through the Modulation of Immune Cell Phenotypes.
Clin Breast Cancer
August 2025
Department of Pharmacy, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, School of Pharmacy, Fujian Medical University, Fuzhou, China. Electronic address:
Background: Emerging evidence suggests that the gut microbiota (GM) may influence the progression of breast cancer by modulating immune responses. Given the vast diversity of GM and immune cell phenotypes, this study aimed to utilize the most advanced and comprehensive data to explore the causal relationships among the GM, immune cell phenotypes, and survival rates in hormone receptor-positive (HR+) breast cancer patients under different treatment regimens.
Methods: We investigated the causal relationships between the GM, immune cell phenotypes, and survival rates in HR+ breast cancer patients treated with 11 distinct therapeutic strategies using Mendelian randomization.